Benitec Sets Mid-2027 Pivotal Start for OPMD Gene Therapy as Cash Stands at $176.5m

Benitec Biopharma has put a date on the next stage of its swallowing-disorder gene therapy. The company expects to begin a pivotal study of BB-301 in mid-2027, after finalising the design in the first quarter of that year. It disclosed the timetable on 13 November 2026 alongside results for the quarter ended 30 September, the first of its 2027 fiscal year.

The programme targets dysphagia caused by oculopharyngeal muscular dystrophy (OPMD), a rare muscle disease. Benitec reported cash of about $176.5 million. The summary of the results does not say how long that would fund operations or how much the pivotal study will cost, so the link between the balance and the trial timetable cannot be drawn from the information available.

The clinical case rests on interim Phase 1b/2a data presented at the ESGCT meeting on 28 October 2026. Benitec said all patients in Cohorts 1 and 2 responded and that no serious adverse events had been reported. The summary gives no patient numbers, no definition of response and no follow-up period. A 100% response rate in a small early-stage cohort is therefore hard to weigh, and the pivotal design, including endpoints and population, will be the first real test of how the company intends to prove benefit.

Benitec also plans to move its fiscal year-end from 30 June to 31 December. The change will alter its reporting calendar, so investors and partners comparing periods will have to adjust for the new schedule. No effective date for the change was given in the material available.